Screening of plasma IL-6 and IL-17 in Bangladeshi lung cancer patients

Abstract

AbstractCancer is the second leading cause of death globally, where most cancer deaths occur in low- and middle-income countries. Lung cancer is the most prevalent in men and the third most prevalent in women among all cancer types. Globally, 1.8 million new lung cancer cases were recorded in 2012, which increased to 2 million in 2018. Cancer disease burden can be diminished, and life expectancy profoundly increases when diagnosis and prognosis are made at an earlier stage. Although biopsy is the gold standard in cancer diagnosis, it is invasive, inconvenient, and expensive. Liquid biopsy, which identifies cancer biomarkers in blood, is an active area of cancer research. Recent evidence suggests that interleukins (ILs), a class of cytokines involved in diverse cellular processes such as inflammation, growth, and proliferation, play critical roles in cancer initiation, progression, and resistance to therapy. Interestingly, many studies found the association of plasma IL-6 and IL-17 levels with lung cancer prognosis. In this study, we analyzed plasma levels of IL-6 and IL-17 in lung cancer patients and healthy volunteers. We have also studied the demographic and medical records of the participants. Among the participants, 42.9% and 57.1% were female in the control group and the disease group, respectively. The age of the participants was 22-65 years, with a mean of 46.5 (SD, ± 19.7) years. Plasma IL-6 levels were strikingly different between healthy volunteers (mean ± SEM, 0.97 ± 0.15 pg/mL) and patients (mean ± SEM, 7.42 ± 1.45 pg/mL). Notably, the range was narrow in the control group (0.32-2.10 pg/mL) but wide in the disease group (0.42-23.20 pg/mL). Plasma IL-17 levels were slightly lower in the disease group (mean ± SEM, 9.40 ± 2.82 pg/mL) compared to the control group (mean ± SEM, 12.40 ± 4.41 pg/mL), although the difference was not statistically significant. Intriguingly, the mean IL-17 value reduced dramatically with chemotherapy, and further reduction occurred with radiotherapy in lung cancer patients. Together, our study supports the use of plasma IL-6 and IL-7 levels as prognostic markers in lung cancer.